Philip Wood - Swedish Orphan Head Haematology

All Insiders . Sweden . 
Stock . Swedish Orphan Biovitrum . Stakeholders . Insider . Philip Wood
SOBI Stock  SEK 302.40  3.40  1.11%   

Insider

Philip Wood is Head Haematology of Swedish Orphan Biovitrum
Age 55
Phone46 86 97 20 00
Webhttps://www.sobi.com

Swedish Orphan Management Efficiency

The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1061 %, meaning that it generated $0.1061 on every $100 dollars invested by stockholders. Swedish Orphan's management efficiency ratios could be used to measure how well Swedish Orphan manages its routine affairs as well as how well it operates its assets and liabilities.
Swedish Orphan Biovitrum has accumulated 9.02 B in total debt with debt to equity ratio (D/E) of 39.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Swedish Orphan until it has trouble settling it off, either with new capital or with free cash flow. So, Swedish Orphan's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Swedish Orphan Biovitrum sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Swedish to invest in growth at high rates of return. When we think about Swedish Orphan's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Per NorlenXintela AB
53
Matthew LindonLidds AB
50
Peter SelinKancera AB
50
Ignacio GarciaRibasCantargia AB
N/A
Thoas MDCantargia AB
61
Dominique TersagoCantargia AB
61
BSc JDXintela AB
65
Susanne LagerlundCantargia AB
N/A
Johanna ChristensenCantargia AB
N/A
Niclas BrynneKancera AB
62
Annette MoldrupLidds AB
62
Nina ValkamaCantargia AB
N/A
Kjell SjstrmCantargia AB
N/A
Kia BengtssonLidds AB
54
MarcussCantargia AB
N/A
Thomas OlinKancera AB
65
Martin NorinKancera AB
64
Johan MDLidds AB
69
Adnan DeronicCantargia AB
N/A
Torbjrn LundstrmKancera AB
70
Jenni BjornulfsonLidds AB
52
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 1185 people. Swedish Orphan Biovitrum (SOBI) is traded on Stockholm Exchange in Sweden and employs 1,556 people.

Management Performance

Return On Equity0.11
Return On Asset0.0555

Swedish Orphan Biovitrum Leadership Team

Elected by the shareholders, the Swedish Orphan's board of directors comprises two types of representatives: Swedish Orphan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Swedish. The board's role is to monitor Swedish Orphan's management team and ensure that shareholders' interests are well served. Swedish Orphan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Swedish Orphan's outside directors are responsible for providing unbiased perspectives on the board's policies.
Konstantina Karampela, Director Operations
Christine Wesstrom, Head Operations
Guido Oelkers, CEO Pres
Thomas Larsen, Head Relations
Pablo Mora, Head Access
Armin MD, Head Affairs
Philip Wood, Head Haematology
Anders MD, Head Officer
Torbjrn Hallberg, G HR
Daniel Rankin, Head Devel
Henrik Stenqvist, Chief Officer

Swedish Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Swedish Orphan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.11
Return On Asset0.0555
Profit Margin0.14 %
Operating Margin0.24 %
Current Valuation72.79 B
Shares Outstanding295.99 M
Shares Owned By Insiders4.00 %
Shares Owned By Institutions70.55 %
Price To Earning20.29 X
Price To Book2.51 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Swedish Stock Analysis

When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY